Medicaid Drug Rebate Program
- Manufacturers and Supporting Regulation at 42 CFR 447.534
(CMS-367)
Revision of a currently approved collection
No
Regular
03/21/2022
Requested
Previously Approved
36 Months From Approved
05/31/2024
15,070
14,980
564,394
558,980
0
0
Section 1927 of the Social Security
Act (the Act) requires drug labelers to enter into and have in
effect a rebate agreement with the Federal government for States to
receive funding for drugs dispensed to Medicaid recipients. In
order for payment to be made under Medicaid, the drug labeler must
complete and sign a drug rebate agreement and fill in the
information on the related documents. The drug manufacturer must
also supply information within 30 days after the end of each
calendar quarter and month on the average manufacturer price of the
drugs. Under the Medicaid program, states may provide coverage of
prescribed drugs as an optional service under section 1905(a)(12)
of the Social Security Act (the Act). Section 1903(a) of the Act
provides for federal financial participation (FFP) in state
expenditures for these drugs. Section 1927 of the Act governs the
Medicaid Drug Rebate (MDR) Program and payment for covered
outpatient drugs (CODs), which are defined in section 1927(k)(2) of
the Act. In general, for payment to be made available under section
1903(a) of the Act for CODs, manufacturers must enter into a
National rebate agreement (agreement) as set forth in section
1927(a) of the Act. Section 1927 of the Act provides specific
requirements for rebate agreements, drug pricing submission and
confidentiality requirements, the formulas for calculating rebate
payments, and requirements for states for CODs.
PL: Pub.L. 111 - 148 2503 Name of Law:
Patient Protection and Affordable Care Act
PL: Pub.L. 111 - 226 202 Name of Law: Education Jobs and Medicaid
Assistance Act
Form CMS-367d is being updated
to include a signature/date line for the submitter to confirm that
the information provide is accurate, and we have additionally
updated the entire 367d to a fillable format, per multiple labeler
requests. We do not anticipate that any of these changes will have
an impact on our burden estimates. CMS-367e is a new form to be
used by manufacturers as needed, on a quarterly basis, to transmit
pricing data (best prices associated with value-based purchasing
(VBP) arrangements) for each of their covered outpatient drugs
(CODs) to CMS either via direct file upload to the MDP System or
manual on-line entry. Using current data, we have revised the
number of respondents reporting drug information to CMS from 749 to
780; an increase of 31 participating labelers in the MDRP. Given
that there are more respondents, the change has increased our total
time and cost estimates. Our cost estimates have also increased by
using more up to date wage figures. We are not proposing changes to
any of our per response time estimates or to the frequency of
reporting. We have also removed one-time system update burden for
CMS-367a, b and c, and added one-time system update burden for
CMS-367e. Overall, we estimate an increase of 5,414 hours (from
558,980 hr to 564,394 hr) and an increase of $1,949,491 (from
$56,261,517 to $58,211,008).
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.